Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

"A slow start for self-amplifying mRNA vaccines" was originally created and published by Pharmaceutical Technology, a ...

In contrast, saRNA delivered into a cell first self-amplifies, resulting in very high mRNA copy numbers, thereby achieving superior gene expression and an amplified protein response with a much ...

Japan is the first country to put a self-amplifying mRNA vaccine into practical use. The health ministry’s expert committee that approved the replicon vaccine has said, “It is desirable to ...

BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...

Arcturus’ lead clinical stage product candidates include a first-in-class, self-amplifying mRNA vaccine for COVID-19 and an mRNA replacement therapy for ornithine transcarbamylase (OTC ...

a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The primary objective of this ...

A significant breakthrough in RNA therapeutics, this self-amplifying technology overcomes key challenges by incorporating alternative ... resulting in enhanced performance of a COVID-19 vaccine with ...

a self-amplifying mRNA (sa-mRNA) vaccine candidate, also known as LUNAR-H5N1, for active immunization to prevent pandemic influenza disease caused by H5N1 virus. The randomized placebo-controlled ...